FATE THERAPEUTICS INC
FATE · Biological Products, (No Diagnostic Substances) · 116.6M shares · +11%/yr ↑ dilution · EDGAR filings ↗
Net buyback after stock comp: -$2M (gross $7K, SBC $2M)
Reference price $1.88 · est. market cap ~$219M — last insider sale, 2026-05-20 (estimated from the dated SEC Form 4 price × shares outstanding — not a live quote)
Grade
D44Clinical/early-stage biotech — cell-therapy clinical, heavy burn, funded.
Strengths
- Liquidity — current ratio 5.8 (58th)
Risks
- Pre-revenue, deep losses — per metrics
- Pre-revenue/clinical-stage — history of losses & need for capital per risk factors
- Binary clinical & funding risk — per 10-K
Notable findings
- Net lossNet loss (net margin -2051.1%)
- Chronic dilutionShare count +11%/yr over 3y (dilution, book value/share -69%)
- Cash burnNegative free cash flow (-112.0M)
- Exec changeRecent 8-K item 5.02 8-K ↗
- Fund exitedNotable fund(s) exited this quarter: VANGUARD GROUP INC
- Notable holderHeld by 5 notable fund(s): RENAISSANCE TECHNOLOGIES LLC, STATE STREET CORP, GOLDMAN SACHS GROUP INC +2 more (as of 2026-03-31)
- Insider sellingInsider selling — 4 open-market sale(s) by 2 insider(s) (cluster of 2 insiders, last 6mo) Form 4 ↗
Quarterly revenue
Last 4 quarters · from SEC filings.
Key metrics
Operating margin
-2222.4%
Net margin
-2051.1%
Return on equity
-65.8%
Return on assets
-42.7%
Revenue growth (QoQ)
-5.1%
Current ratio
5.8×
Free cash flow
-$112M
EBITDA
-$135M
Tangible book value
$207M
Cash & investments
$205M
Cash runway
7q
Stock comp / revenue
375.0%
Insider transactions · last 18 months
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-05-20 | TAHL CINDY | Sell | 26K | $1.88 |
| 2026-05-20 | Valamehr Bahram | Sell | 29K | $1.88 |
| 2026-05-06 | TAHL CINDY | Option exercise | 122K | $1.32 |
| 2026-05-06 | TAHL CINDY | Option exercise | 44K | $1.05 |
| 2026-05-05 | EPSTEIN ROBERT S | Option exercise | 25K | $1.69 |
| 2026-05-05 | RASTETTER WILLIAM H | Option exercise | 25K | $1.69 |
| 2026-04-20 | Redmile Group, LLC | Other | 9.0M | — |
| 2026-04-20 | Redmile Group, LLC | Other | 9.0M | — |
| 2026-01-15 | TAHL CINDY | Grant | 100K | — |
| 2026-01-15 | Adawi Kamal | Grant | 25K | — |
| 2026-01-15 | Valamehr Bahram | Grant | 335K | — |
| 2026-01-09 | TAHL CINDY | Sell | 11K | $1.06 |
| 2026-01-09 | Valamehr Bahram | Sell | 5.2K | $1.07 |
| 2025-10-20 | Adawi Kamal | Grant | 75K | — |
| 2025-08-04 | TAHL CINDY | Sell | 9.0K | $1.06 |
| 2025-08-04 | Valamehr Bahram | Sell | 14K | $1.06 |
| 2025-01-15 | TAHL CINDY | Grant | 70K | — |
| 2025-01-15 | Bressi Jerome Charles | Grant | 65K | — |
| 2025-01-10 | Bressi Jerome Charles | Sell | 6.0K | $1.55 |
| 2025-01-10 | TAHL CINDY | Sell | 5.7K | $1.55 |
| 2025-01-10 | Valamehr Bahram | Sell | 8.7K | $1.54 |
All non-derivative Form 4 activity (SEC), newest first.
Notable events (8-K)
| Date | Items | |
|---|---|---|
| 2026-06-15 | Exec/director changeShareholder voteExhibits | filing ↗ |
| 2026-06-04 | OtherExhibits | filing ↗ |
| 2026-05-13 | ResultsExhibits | filing ↗ |
| 2026-02-26 | ResultsExhibits | filing ↗ |
| 2025-11-13 | ResultsExhibits | filing ↗ |
| 2025-10-27 | Reg FDOtherExhibits | filing ↗ |
| 2025-10-14 | Exec/director changeReg FDExhibits | filing ↗ |
| 2025-08-12 | Results2.05Exhibits | filing ↗ |
Recent filings
| Form | Filed | Period | Accession |
|---|---|---|---|
| 8-K | 2026-06-15 | 2026-06-12 | 0001193125-26-271055 ↗ |
| 8-K | 2026-06-04 | 2026-06-04 | 0001193125-26-257558 ↗ |
| 8-K | 2026-05-13 | 2026-05-13 | 0001193125-26-220691 ↗ |
| 10-Q | 2026-05-13 | 2026-03-31 | 0001193125-26-220696 ↗ |
| 10-K | 2026-02-26 | 2025-12-31 | 0001193125-26-073699 ↗ |
| 8-K | 2026-02-26 | 2026-02-26 | 0001193125-26-073689 ↗ |
| 10-Q | 2025-11-13 | 2025-09-30 | 0001193125-25-279096 ↗ |
| 8-K | 2025-11-13 | 2025-11-13 | 0001193125-25-279091 ↗ |
| 8-K | 2025-10-27 | 2025-10-26 | 0001193125-25-250674 ↗ |
| 8-K | 2025-10-14 | 2025-10-10 | 0001193125-25-238989 ↗ |
| 8-K | 2025-08-12 | 2025-08-07 | 0001193125-25-178947 ↗ |
| 10-Q | 2025-08-12 | 2025-06-30 | 0000950170-25-107309 ↗ |